Form 8-K

8-K — SS Innovations International, Inc.

Accession: 0001213900-26-088726

Filed: 2026-08-13

Period: 2026-08-13

CIK: 0001676163

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Results of Operations and Financial Condition

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — ea0301887-8k_ssinnova.htm (Primary)

EX-99.1 — PRESS RELEASE, DATED AUGUST 13, 2026 (ea030188701ex99-1.htm)

GRAPHIC (ea030188701_ex99-1img1.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0301887-8k_ssinnova.htm · Sequence: 1

false

0001676163

2026-08-13

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

Pursuant to Section 13 or 15(d) of The Securities

Exchange Act of 1934

Date of report (Date of earliest event reported):

August 13, 2026

SS INNOVATIONS INTERNATIONAL, INC.

(Exact name of registrant as specified in its charter)

Florida

001-42615

47-3478854

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

405, 3rd Floor, iLabs Info Technology Centre

Udyog Vihar, Phase III

Gurugram, Haryana India

122016

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including

area code: +91 73375 53469

(Former name or former address, if changed since

last report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General

Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b)

of the Act:

Title of each Class

Trading Symbol

Name of each exchange on which registered

Common Stock

SSII

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ☐

As used in this Current Report on Form 8-K (this

“Current Report”), the terms “SSi,” “the Company,” “we,” “us”

and “our” refer to SS Innovations International, Inc. and its subsidiaries.

Item 2.02 Results of Operations and Financial

Condition.

The disclosure set forth in Item 7.01 of

this Current Report is incorporated herein by reference.

Item 7.01 Regulation FD Disclosure.

On August 13, 2026, the Company issued a press

release announcing financial results for the three and six month periods ended June 30, 2026, and the filing with the Securities and Exchange

Commission of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026.

A copy of the press release is included with this

Current Report as Exhibit 99.1.

The information set forth in Items 2.02 and

7.01 of this Current Report and in the press release included as Exhibit 99.1 to this Current Report, are deemed to be “furnished”

and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange

Act”), or otherwise subject to the liabilities of that Section. The information set forth in Items 2.02 and 7.01

of this Current Report and in the press release included as Exhibit 99.1 to this Current Report, shall not be deemed incorporated

by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation

language in such filing.

Forward-Looking Statements

This Current Report and the press release included

as Exhibit 99.1 to this Current Report, includes statements that are not historical facts and are considered forward-looking within

the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical

statements of fact and statements regarding the Company’s intent, belief or expectations, including, but not limited to, statements

regarding the Company’s fourth quarter 2025 and full year 2025 preliminary results, product development, clinical and regulatory

timelines, market opportunity, competitive position, possible or assumed future results of operations and other statements that are predictive

in nature. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,”

“will,” “intend,” “may,” “plan,” “project,” “should,” “could,”

“seek,” “designed,” “potential,” “forecast,” “target,” “objective,”

“goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements

relate to future events or SSi’s future financial performance and involve known and unknown risks, uncertainties and other factors

that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results,

levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance

on forward-looking statements.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

99.1*

Press Release, dated August 13, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Furnished

not filed

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 13, 2026

SS INNOVATIONS INTERNATIONAL, INC.

By:

/s/ Sudhir Srivastava

Sudhir Srivastava, M.D.

Chairman, Chief Executive Officer, Interim Chief Financial Officer

EX-99.1 — PRESS RELEASE, DATED AUGUST 13, 2026

EX-99.1

Filename: ea030188701ex99-1.htm · Sequence: 2

Exhibit 99.1

SS Innovations Reports Second Quarter 2026 Financial

Results

Record quarterly revenue driven by continuing

strong growth in SSi Mantra unit sales

FORT LAUDERDALE, FLA – August 13, 2026

– SS Innovations International, Inc. (the “Company” or “SS

Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable

and accessible to a global population, today announced unaudited financial results for the three and six months ended June 30, 2026. The

Company also filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, with the Securities and Exchange Commission

on August 13, 2026.

Second Quarter 2026 Overview

● Revenue increased 39.4% to $13.9 million from

$10.0 million in the second quarter of 2025.

● Gross margin equaled 50.9%, compared to 59.1%

in the second quarter of 2025.

● Gross profit rose 20.0% to $7.1 million from

$5.9 million in the second quarter of 2025.

● Net loss of $2.7 million, or $(0.01) per diluted

share, compared to a net loss of $0.3 million, or $(0.00) per diluted share, in the second quarter of 2025.

● SSi Mantra surgical robotic system installations

totaled 30, up 30.4% from 23 installations in the second quarter of 2025.

First Half 2026 Overview

● Revenue increased 65.6% to $25.0 million from

$15.1 million in the first half of 2025.

● Gross margin expanded to 49.6% from 46.3% in

the first half of 2025.

● Gross profit rose 77.5% to $12.4 million from

$7.0 million in the first half of 2025.

● Net loss of $6.2 million, or $(0.03) per diluted

share, compared to a net loss of $5.9 million, or $(0.03) per diluted share, in the first half of 2025.

● SSi Mantra surgical robotic system installations

totaled 56, up 47.4% from 38 installations in the first half of 2025.

As of June 30, 2026

● Long-term debt of $0.

● Cash and cash equivalents totaled $13.6 million,

excluding restricted cash.

● SSi Mantra cumulative installed base totaled

224 systems across twelve countries and cumulative surgeries reached 12,272, including 175 telesurgeries, 637 cardiac procedures and 222

pediatric surgeries.

CEO Commentary

Dr. Sudhir Srivastava, Chairman of the Board and

Chief Executive Officer of SS Innovations, commented, “SS Innovations delivered record quarterly revenue of $13.9 million in the

second quarter of 2026, up 39% year over year, reflecting strong adoption of our advanced SSi Mantra surgical robotic system by leading

hospitals and surgeons in India and abroad. We continue to expand awareness of the SSi Mantra’s cutting-edge surgical robotic technology,

differentiated features, user friendliness, training capabilities, and cost efficiency. Recently the SSi Mantra has been showcased in

several high-profile international long-distance telesurgeries as well as at this year’s Global Multi-Specialty Robotic Surgery

Conference in New Delhi, which we hosted, and the 2026 Society of Robotic Surgery Annual Meeting in Florida. We appreciate the widespread

positive reception of the SSi Mantra at these events and were excited to win the ‘Outstanding Company’ category at the 2026

Surgical Robotics Industry Awards in June.”

Dr. Srivastava continued, “We remain enthusiastic

about our ability to lead our foundational market of India, which is immense and growing, while expanding our global footprint in underserved

countries and aiming for entry into the United States and European Union. We expect the U.S. Food and Drug Administration to complete

its review of our 510(k) premarket notification for the SSi Mantra by the end of the first quarter of 2027. We also continue along the

pathway towards a European Union CE marking certification for the SSi Mantra, which we believe we can obtain by the end of 2026. Our SSI

Mantra has been engineered for precision, built to perform, and created to democratize access to advanced surgical robotic care—all

underpinning our confidence in the future.”

Select Business Highlights in Second Quarter

2026

● In April 2026, the Company hosted the Global

Multi-Specialty Robotic Surgery Conference in New Delhi, India, bringing together distinguished surgeons, global thought leaders and prominent

innovators to discuss and shape the future of robotic and minimally invasive surgery. The event drew more than 1,600 attendees and 1,800

virtual participants from 19 nations.

● On May 7, 2026, the Company announced the successful

completion of a landmark telesurgery performed in Perth, Australia, more than 4,500 miles from the patient in India, utilizing the SSi

Mantra surgical robotic system (the “SSi Mantra”) and the SSi MantrAsana tele-surgeon console.

● On June 4, 2026, the Company announced the successful

completion of a robotic-assisted heart procedure performed with the SSi Mantra across approximately 12,500 miles (20,000 kilometers) of

fiber network distance between Guyana and India, making it the world’s then longest-distance robotic telesurgery.

● In June 2026, the Company won the Outstanding

Company category at the 2026 Surgical Robotics Industry Awards, surpassing nine other well-established finalists vying for this coveted

industry accolade.

● In June 2026, the Company’s subsidiary,

the SS International Centre for Robotics Surgery, graduated its first class in a specialized training course designed to provide surgeons

and other healthcare professionals with classroom instruction and hands-on learning in robotic-assisted cardiac surgery using the advanced

SSi Mantra surgical robotic system.

Subsequent Event

● On July 29, 2026, a team of surgeons led by Dr.

Sudhir Srivastava utilized the SSi Mantra to perform a successful robotic telesurgery between Colombia and India, spanning more than 13,600

miles (22,000 kilometers) of fiber network distance and eclipsing the previous longest-distance telesurgery record also held by the Company.

The telesurgery, a robotic sleeve gastrectomy, was performed remotely from Hospital Internacional de Colombia in Bucaramanga, Colombia

on a patient located at Mohak Bariatrics and Robotics in Indore, India.

Revenue Breakdown and Summary of Installations

/ Surgeries

Category

H1 2025

H1 2026

Variance

Percentage

System sales

$ 13,283,520

$ 21,937,356

$ 8,653,836

65.1 %

Instrument sales

1,485,038

2,293,753

808,715

54.5 %

Warranty sales

315,863

776,688

460,825

145.9 %

Lease income

36,494

33,278

(3,216 )

-8.8 %

Total revenue

$ 15,120,915

$ 25,041,075

$ 9,920,160

65.6 %

SSi Mantra installations

47.4 %

SSi Mantra surgeries

1,861

4,387

2,526

135.7 %

About SS Innovations

SS Innovations International, Inc. (Nasdaq: SSII)

develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a

larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical

robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical robotic

procedures including cardiac surgery. Headquartered in India, SS Innovations is a U.S. company focused on expanding the global presence

of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Visit the Company’s website at ssinnovations.com

or LinkedIn for more information and updates.

About the SSi Mantra

The SSi Mantra surgical robotic system is a user-friendly,

modular, multi-arm system with advanced technology features, including: 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command

center, a large 3D 4K monitor, a touch panel monitor for all patient related information display, a virtual real-time image of the robotic

patient side arm carts, and the ability for superimposition of 3D models of diagnostic imaging. The optional SSi MantrAsana tele-surgeon

console is a portable, compact alternative to the SSi Mantra’s standard surgeon command center that provides equivalent control

functionality while enabling enhanced portability, ergonomic flexibility, and telesurgery capability. The SSi Mantra utilizes over 40

different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery, and 5mm instruments

for the pediatric population and ENT surgeries. A vision cart provides the table-side team with the same magnified 3D 4K view as the surgeon

to provide better safety and efficiency. The SSi Mantra has been clinically validated in India in more than 170 different types of surgical

procedures.

Forward Looking Statements

This press release may contain statements that

are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995.

The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,”

“intend,” “may,” “plan,” “project,” “should,” “could,” “seek,”

“designed,” “potential,” “forecast,” “target,” “objective,” “goal,”

or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future

events or SS Innovations’ future financial performance and involve known and unknown risks, uncertainties and other factors that

may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels

of activity, performance or achievements expressed or implied by these forward-looking statements.

Investor Contact:

The Equity Group

Kalle Ahl, CFA

T: (303) 953-9878

kalle.ahl@theequitygroup.com

Devin Sullivan, Managing Director

T: (212) 836-9608

devin.sullivan@theequitygroup.com

Media Contact:

RooneyPartners LLC

Kate Barrette

T: (212) 223-0561

kbarrette@rooneypartners.com

SS INNOVATIONS INTERNATIONAL, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

As of

June 30,

2026

December 31,

2025

(Unaudited)

ASSETS

Current Assets:

Cash and cash equivalents

$ 13,647,430

$ 3,206,406

Restricted cash

8,648,461

5,937,650

Accounts receivable, net

16,986,089

12,398,542

Inventory

18,481,603

17,064,002

Prepaids and other current assets

13,690,369

10,166,823

Total Current Assets

71,453,952

48,773,423

Property, plant, and equipment, net

8,637,145

9,100,546

Right of use asset, net

3,045,707

2,754,020

Deferred tax assets, net

843,544

533,727

Accounts receivable, net-non-current

8,511,054

8,566,654

Restricted cash- non-current

375,132

458,964

Prepaids and other non-current assets

4,115,479

4,038,883

Total Assets

$ 96,982,013

$ 74,226,217

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current Liabilities

Bank overdraft facility

$ 14,634,960

$ 11,442,948

Current portion of operating lease liabilities

687,707

579,169

Accounts payable

5,265,754

5,127,193

Deferred revenue

3,916,269

3,266,686

Accrued expenses & other current liabilities

7,387,037

5,825,702

Total Current Liabilities

31,891,727

26,241,698

Operating lease liabilities, less current portion

2,549,823

2,337,697

Deferred Revenue- non-current

8,695,725

7,139,807

Other non-current liabilities

443,515

288,764

Total Liabilities

$ 43,580,790

$ 36,007,966

Commitments and contingencies

Stockholders’ equity:

Preferred stock, authorized 5,000,000 shares of Series A, Non-Convertible Preferred Stock, $0.0001 par value per share; 1,000 shares issued and outstanding as of June 30, 2026 and December 31, 2025

Common stock, 250,000,000 shares authorized, $0.0001 par value, 200,169,035 shares and 194,165,141 shares issued and outstanding as of June 30, 2026 and December 31, 2025 respectively

20,017

19,416

Accumulated other comprehensive loss

(3,994,166 )

(2,022,660 )

Additional paid in capital

118,509,309

95,111,511

Capital reserve

899,917

Accumulated deficit

(62,033,855 )

(55,789,934 )

Total stockholders’ equity

53,401,223

38,218,251

Total liabilities and stockholders’ equity

$ 96,982,013

$ 74,226,217

SS INNOVATIONS INTERNATIONAL, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

AND COMPREHENSIVE LOSS

(Unaudited)

For The Three months ended

June 30,

2026

June 30,

2025

REVENUES

System sales

12,361,986

8,781,038

Instrument sales

1,142,525

1,007,830

Warranty sales

419,002

193,359

Lease income

16,196

18,078

Total revenue

$ 13,939,709

$ 10,000,305

Cost of revenue

(6,838,759 )

(4,085,247 )

GROSS PROFIT

7,100,950

5,915,058

OPERATING EXPENSES:

Research & development expense

2,395,694

498,600

Stock-based compensation expense

2,178,156

1,630,295

Depreciation and amortization expense

346,364

260,361

Selling, general and administrative expense

4,452,090

3,428,788

TOTAL OPERATING EXPENSES

9,372,304

5,818,044

(Loss) / Profit from operations

(2,271,354 )

97,014

OTHER INCOME/ (EXPENSE):

Interest Expense

(344,761 )

(216,800 )

Interest and other income, net

460,041

216,824

TOTAL OTHER INCOME, NET

115,280

(LOSS) / PROFIT BEFORE INCOME TAXES

(2,156,074 )

97,038

Income tax expense

505,276

353,729

NET LOSS

$ (2,661,350 )

$ (256,691 )

Net loss per share - basic and diluted

$ (0.01 )

$ (0.00 )

Weighted average- basic shares

200,136,068

193,571,635

Weighted average- diluted shares

209,422,550

202,835,698

CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE LOSS

NET LOSS

$ (2,661,350 )

$ (256,691 )

OTHER COMPREHENSIVE LOSS

Foreign currency translation loss

(404,867 )

(66,014 )

Retirement Benefit

(25,651 )

(35,660 )

RECLASSIFICATION ADJUSTMENTS:

Retirement Benefit (1)

3,033

Income tax effects relating to retirement benefit (1)

6,456

5,772

TOTAL OTHER COMPREHENSIVE LOSS

(421,029 )

(95,902 )

TOTAL COMPREHENSIVE LOSS

$ (3,082,379 )

$ (352,593 )

(1) These

are reclassified to net loss and are included in other expense in the condensed consolidated statements of operations.

SS INNOVATIONS INTERNATIONAL, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

AND COMPREHENSIVE LOSS

(Unaudited)

For The Six months ended

June 30,

2026

June 30,

2025

REVENUES

System sales

21,937,356

13,283,520

Instrument sales

2,293,753

1,485,038

Warranty sales

776,688

315,863

Lease income

33,278

36,494

Total revenue

$ 25,041,075

$ 15,120,915

Cost of revenue

(12,612,904 )

(8,118,649 )

GROSS PROFIT

12,428,171

7,002,266

OPERATING EXPENSES:

Research & development expense

3,391,134

1,508,695

Stock-based compensation expense

5,322,471

4,009,507

Depreciation and amortization expense

670,111

469,243

Selling, general and administrative expense

8,941,387

6,638,587

TOTAL OPERATING EXPENSES

18,325,103

12,626,032

Loss from operations

(5,896,932 )

(5,623,766 )

OTHER INCOME/ (EXPENSE):

Interest Expense

(628,812 )

(596,705 )

Interest and other income, net

938,451

636,156

TOTAL OTHER INCOME, NET

309,639

39,451

LOSS BEFORE INCOME TAXES

(5,587,293 )

(5,584,315 )

Income tax expense

656,628

353,729

NET LOSS

$ (6,243,921 )

$ (5,938,044 )

Net loss per share - basic and diluted

$ (0.03 )

Weighted average- basic shares

198,083,415

186,244,872

Weighted average- diluted shares

207,369,897

195,502,268

CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE LOSS

NET LOSS

$ (6,243,921 )

$ (5,938,044 )

OTHER COMPREHENSIVE LOSS

Foreign currency translation loss

(1,961,978 )

(59,138 )

Retirement Benefit

(20,870 )

(19,822 )

RECLASSIFICATION ADJUSTMENTS:

Retirement Benefit (1)

6,089

Income tax effects relating to retirement benefit (1)

5,253

5,772

TOTAL OTHER COMPREHENSIVE LOSS

(1,971,506 )

(73,188 )

TOTAL COMPREHENSIVE LOSS

$ (8,215,427 )

$ (6,011,232 )

(1)

These are reclassified to net loss and are included in other expense in the condensed consolidated statements of operations.

SS INNOVATIONS INTERNATIONAL, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

For the six months ended

June 30,

2026

June 30,

2025

Cash flows from operating activities:

Net loss

$ (6,243,921 )

$ (5,938,044 )

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization

670,111

469,243

Operating lease expense

471,459

423,593

Interest expense

84,938

179,455

Interest and other income, net

(814,218 )

(338,191 )

Deferred income tax benefit

(336,457 )

(365,641 )

Stock-based compensation expense

5,368,330

4,009,507

Provision for / (reversal of) credit loss reserve, net

297,882

(228,846 )

Provision for slow moving inventory

(6,225 )

Changes in operating assets and liabilities:

Accounts receivable, net

(4,286,490 )

(2,337,679 )

Inventory, net

(1,411,376 )

(10,221,214 )

Deferred revenue

2,205,501

1,739,652

Prepaids and other assets

(3,955,550 )

(2,572,481 )

Accounts payable

127,728

3,782,409

Income taxes payable, net

933,184

620,586

Accrued expenses & other liabilities

782,787

1,629,136

Operating lease payment

(434,132 )

(407,188 )

Net cash used in operating activities

(6,546,449 )

(9,555,703 )

Cash flows from investing activities:

Purchase of property, plant and equipment

(215,060 )

(1,189,452 )

Net cash used in investing activities

(215,060 )

(1,189,452 )

Cash flows from financing activities:

Proceeds from bank overdraft facility (net)

3,192,012

(1,014,593 )

Proceeds from private investment in public equity, net of transaction costs

18,446,498

Proceeds from issuance of convertible notes to principal shareholder

28,000,000

Repayment of convertible notes to principal shareholder, including interest

(4,212,637 )

Repayment of convertible notes to other investors, including interest

(1,068,849 )

Net cash provided by financing activities

21,638,510

21,703,921

Net change in cash

14,877,001

10,958,766

Effect of exchange rate on cash

(1,808,998 )

23,377

Cash and cash equivalents at the beginning of the period

9,603,020

6,623,535

Cash and cash equivalents at end of the period

$ 22,671,023

$ 17,605,678

GRAPHIC

Filename: ea030188701_ex99-1img1.jpg · Sequence: 3

Binary file (12667 bytes)

Download ea030188701_ex99-1img1.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Aug. 13, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 13, 2026

Entity File Number

001-42615

Entity Registrant Name

SS INNOVATIONS INTERNATIONAL, INC.

Entity Central Index Key

0001676163

Entity Tax Identification Number

47-3478854

Entity Incorporation, State or Country Code

Entity Address, Address Line One

405, 3rd Floor

Entity Address, Address Line Two

iLabs Info Technology Centre

Entity Address, Address Line Three

Udyog Vihar, Phase III

Entity Address, City or Town

Gurugram

Entity Address, Country

Entity Address, Postal Zip Code

122016

City Area Code

+91

Local Phone Number

73375 53469

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock

Trading Symbol

SSII

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 3 such as an Office Park

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine3

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

ISO 3166-1 alpha-2 country code.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCountry

Namespace Prefix:

dei_

Data Type:

dei:countryCodeItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration